EGFR and neoplasm: And we mainly focused on summarizing the clinical data with regard to the efficacy of ICBs (either monotherapy or combination with other therapy, including chemotherapy, TKIs, and so on) in EGFRwt and EGFRmut patients, introducing how EGFR modulates the immune landscape to create niches for immune escape in both tumor‐intrinsic and extrinsic manners, and putting forward further combined strategies to improve the efficacy of ICBs in patients with abnormal EGFR signaling.